InsidersTradesSigma
HARROW, INC. Stock: price and management transactions · United States · SEC (Form 4)
Follow the HARROW, INC. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, HARROW, INC. has published 29 reports. Market capitalisation: €1.7bn. The latest transaction was disclosed on 15 May 2026 (Acquisition). Among the most active insiders: Opaleye Management Inc.. All data is free.
29
Insider Decl.
0
Thresholds
€2m
11 ops.
Buy Volume
€2m
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate HARROW, INC. Strong Buy (bullish), based on 8 analysts. Average price target: US$67.75.
55Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 20,747 of 26,211 companies
31.2
score / 100
Value29
Quality33
FCF yld2.7%
Earn yld-0.3%
EV/EBITDA43.2x
ROE-35%
Gross mgn75%
Net mgn-1.9%
Debt/EBITDA5.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 15 May 2026
Declarations29 total
3,500 shares@ US$29.900.0077% mcap50.1% of flowCommon StockSEC:0001493152-26-023319:0
Ideal exit: 8 Feb 2027 (T+270)
3,500 shares@ US$29.76230.0077% mcap49.9% of flowCommon StockSEC:0001493152-26-023319
Ideal exit: 8 Feb 2027 (T+270)
10,000 shares@ US$30.200.022% mcap100.0% of flowCommon StockSEC:0001493152-26-023321:0
Ideal exit: 8 Feb 2027 (T+270)
5,000 shares@ US$29.644.0% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-010338:0
5,000 shares@ US$30.0114.1% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-010335:0
10,000 shares@ US$25.89596.8% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-010340:0
346,500 shares0Common StockSEC:0001641172-25-003112:0
762,300 shares0Common StockSEC:0001641172-25-003109:0
277,200 shares0Common StockSEC:0001641172-25-003111:0
5,000 shares@ US$30.0114.0% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-000741:0
5,000 shares@ US$29.644.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-011028:0
5,000 shares@ US$28.053.9% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-009061:0
20,000 shares@ US$35.590720.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-003670:0
90,000 shares@ US$7.3764.1% of flowCommon stockSEC:0001493152-24-036244:0
20,000 shares@ US$9.975.4% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-015983:0
Ideal exit: 20 Jan 2025 (T+270)
11,715 shares@ US$10.293.3% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-015806:0
Ideal exit: 18 Jan 2025 (T+270)
29,400 shares@ US$10.55758.5% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-015410:0
Ideal exit: 14 Jan 2025 (T+270)
50,000 shares@ US$12.8217.4% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-011815:0
Ideal exit: 23 Dec 2024 (T+270)
9,000 shares@ US$11.594.8% of flowCommon stockSEC:0001493152-24-011071:0
Ideal exit: 17 Dec 2024 (T+270)
50,600 shares@ US$9.6513.2% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-24-010936:0
Ideal exit: 15 Dec 2024 (T+270)
5,000 shares@ US$8.754.3% of flowCommon stockSEC:0001493152-24-008930:0
150,000 shares@ US$10.6774.0% of flowCommon stockSEC:0001493152-24-007453:0
45,000 shares@ US$10.6765.8% of flowCommon stockSEC:0001493152-24-007454:0
30,000 shares@ US$10.6731.6% of flowCommon stockSEC:0001493152-24-007456:0
15,400 shares@ US$7.715.5% of flowCommon stockSEC:0001493152-24-005371:0
25 of 29 declarations
About HARROW, INC.
Harrow, Inc. (NASDAQ: HROW) is a U.S.-based ophthalmology-focused healthcare company operating in a specialized but economically attractive segment of pharmaceuticals. Headquartered in Nashville, Tennessee, in the United States, Harrow was originally founded in 2012 in San Diego, California, and later shifted its corporate center to Nashville as the company expanded. Over time, Harrow has evolved from a business centered on compounded ophthalmic medicines into an integrated platform serving eyecare professionals across surgical, in-office, and chronic-care use cases. ([investors.harrow.com](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-nashville-expansion/?utm_source=openai)) The company’s operating model is built around ophthalmic disease management solutions for the North American market. Harrow’s portfolio spans conditions affecting both the front and back of the eye, including dry eye disease, ocular inflammation, cataracts, glaucoma, allergic conjunctivitis, infections, and selected retinal indications. The company markets a mix of branded prescription medicines and compounded formulations through its commercial infrastructure and pharmacy relationships. Key products and brands highlighted by Harrow include VEVYE, IHEEZO, IOPIDINE, MAXITROL, MOXEZA, ILEVRO, NEVANAC, MAXIDEX, FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and recently added assets such as BYQLOVI. ([investors.harrow.com](https://investors.harrow.com/about/?utm_source=openai)) From a competitive standpoint, Harrow occupies a differentiated position in U.S. ophthalmology because it combines branded products, compounding capabilities, and direct commercial reach. That combination gives the company exposure to both recurring chronic-use therapies and procedure-related products, while also allowing it to support eyecare physicians with a broad product toolkit. Harrow describes itself as a leading provider of ophthalmic disease management solutions in North America and continues to position its platform around affordability, accessibility, and improved clinical outcomes. ([investors.harrow.com](https://investors.harrow.com/about/?utm_source=openai)) Recent corporate developments underscore a deliberate portfolio-expansion strategy. In 2024, Harrow announced the U.S. availability of VEVYE and expanded access through the 340B Prime Vendor Program. In 2025, the company announced the acquisition of U.S. commercial rights to BYQLOVI, a clobetasol propionate ophthalmic suspension positioned as the first new ophthalmic steroid in its class in more than 15 years. These moves support Harrow’s broader effort to deepen its ophthalmic franchise, broaden market access, and strengthen its commercial footprint on the NASDAQ-listed market in the United States. ([investors.harrow.com](https://investors.harrow.com/news-releases/news-release-details/harrow-announces-availability-vevyer-cyclosporine-ophthalmic/?utm_source=openai))
